Ricardo Russo

List of Publications by Year in Descending Order

74 papers	5,590 citations	40 h-index	74 g-index
81 ext. papers	6,730 ext. citations	4.2 avg, IF	4.92 L-index

#	Paper	IF	Citations
74	Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. *Rheumatology*, **2020**, 59, 3505-3514	3.9	16
73	Classification criteria for autoinflammatory recurrent fevers. *Annals of the Rheumatic Diseases*, **2019**, 78, 1025-1032	2.4	159
72	Consensus-based recommendations for the management of juvenile localised scleroderma. *Annals of the Rheumatic Diseases*, **2019**, 78, 1019-1024	2.4	45
71	Juvenile arthritis management in less resourced countries (JAMLess): consensus recommendations from the Cradle of Humankind. *Clinical Rheumatology*, **2019**, 38, 563-575	3.9	18
70	An international delphi survey for the definition of the variables for the development of new classification criteria for periodic fever aphtous stomatitis pharingitis cervical adenitis (PFAPA). *Pediatric Rheumatology*, **2018**, 16, 27	3.5	13
69	The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). *Rheumatology International*, **2018**, 38, 51-58	3.6	
68	IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis. *Arthritis and Rheumatology*, **2018**, 70, 1319-1330	9.5	22
67	Treating juvenile idiopathic arthritis to target: recommendations of an international task force. *Annals of the Rheumatic Diseases*, **2018**, 77, 819-828	2.4	99
66	Blau Syndrome-Associated Uveitis: Preliminary Results From an International Prospective Interventional Case Series. *American Journal of Ophthalmology*, **2018**, 187, 158-166	4.9	40
65	In silico validation of the Autoinflammatory Disease Damage Index. *Annals of the Rheumatic Diseases*, **2018**, 77, 1599-1605	2.4	17
64	Development of a consensus core dataset in juvenile dermatomyositis for clinical use to inform research. *Annals of the Rheumatic Diseases*, **2018**, 77, 241-250	2.4	20
63	Takayasu Arteritis. *Frontiers in Pediatrics*, **2018**, 6, 265	3.4	44
62	Development of the autoinflammatory disease damage index (ADDI). *Annals of the Rheumatic Diseases*, **2017**, 76, 821-830	2.4	54
61	Consensus-based recommendations for the management of juvenile dermatomyositis. *Annals of the Rheumatic Diseases*, **2017**, 76, 329-340	2.4	119
60	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials	9.5	36
59	2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Annals of the Rheumatic Diseases*, **2017**, 76, 782-791	2.4	24
58	Genetic architecture distinguishes systemic juvenile idiopathic arthritis from other forms of juvenile idiopathic arthritis: clinical and therapeutic implications. *Annals of the Rheumatic Diseases*, **2017**, 76, 906-913	2.4	89

57	Development and Initial Validation of the Macrophage Activation Syndrome/Primary Hemophagocytic Lymphohistiocytosis Score, a Diagnostic Tool that Differentiates Primary Hemophagocytic Lymphohistiocytosis from Macrophage Activation Syndrome. *Journal of Pediatrics*, **2017**, 189, 72-78.e3	3.6	37
56	Biologic agents in juvenile spondyloarthropathies. *Pediatric Rheumatology*, **2016**, 14, 17	3.5	16
55	Expert consensus on dynamics of laboratory tests for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. *RMD Open*, **2016**, 2, e000161	5.9	46
54	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Annals of the Rheumatic Diseases*, **2016**, 75, 481-9	2.4	247
53	Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. *Lancet, The*, **2016**, 387, 671-678	40	124
52	The Phenotype and Genotype of Mevalonate Kinase Deficiency: A Series of 114 Cases From the Eurofever Registry. *Arthritis and Rheumatology*, **2016**, 68, 2795-2805	9.5	112
51	2016 Classification Criteria for Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis: A European League Against Rheumatism/American College of Rheumatology/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. *Arthritis and Rheumatology*, **2016**, 68, 566-76	9.5	216
50	Recommendations for the management of autoinflammatory diseases. *Annals of the Rheumatic Diseases*, **2015**, 74, 1636-44	2.4	179
49	Blau syndrome: cross-sectional data from a multicentre study of clinical, radiological and functional outcomes. *Rheumatology*, **2015**, 54, 1008-16	3.9	96
48	Multicentric prevalence study of anti P ribosomal autoantibodies in juvenile onset systemic lupus erythematosus compared with adult onset systemic lupus erythematosus. *Reumatología Clínica*, **2015**, 11, 73-7	0.9	6
47	Multicentric Prevalence Study of Anti-P Ribosomal Autoantibodies in Juvenile Onset Systemic Lupus Erythematosus Compared With Adult Onset Systemic Lupus Erythematosus. *Reumatología Clínica (English Edition)*, **2015**, 11, 73-77	0.1	
46	HLA-DRB1*11 and variants of the MHC class II locus are strong risk factors for systemic juvenile idiopathic arthritis. *Proceedings of the National Academy of Sciences of the United States of America*, **2015**, 112, 15970-5	11.5	103
45	Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. *Annals of the Rheumatic Diseases*, **2015**, 74, 799-805	2.4	170
44	Clinical features, treatment, and outcome of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis: a multinational, multicenter study of 362 patients. *Arthritis and Rheumatology*, **2014**, 66, 3160-9	9.5	248
43	Efficacy and safety of canakinumab therapy in paediatric patients with cryopyrin-associated periodic syndrome: a single-centre, real-world experience. *Rheumatology*, **2014**, 53, 665-70	3.9	29
42	Monogenic autoinflammatory diseases. *Rheumatology*, **2014**, 53, 1927-39	3.9	21
41	Share Workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile idiopathic arthritis. *Pediatric Rheumatology*, **2014**, 12,	3.5	78
40	Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis. *Arthritis Care and Research*, **2014**, 66, 949-55	4.7	39

39	Development of new classification criteria for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. *Pediatric Rheumatology*, **2014**, 12,	3.5	6
38	SHARE workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile localized scleroderma and juvenile systemic sclerosis. *Pediatric Rheumatology*, **2014**, 12,	3.5	78
37	SHARE workpackage 5: evidence based recommendations for diagnosis and treatment of juvenile dermatomyositis. *Pediatric Rheumatology*, **2014**, 12, P89	3.5	78
36	PReS-FINAL-2236: Continuous autoinflammatory syndromes: a single-center experience in Argentina. *Pediatric Rheumatology*, **2013**, 11,	3.5	78
35	PReS-FINAL-2120: Juvenile scleroderma international network (JUSINET) database: a reliable instrument for clinical research in juvenile scleroderma syndromes. *Pediatric Rheumatology*, **2013**, 11,	3.5	78
34	Patients with very early-onset systemic juvenile idiopathic arthritis exhibit more inflammatory features and a worse outcome. *Journal of Rheumatology*, **2013**, 40, 329-34	4.1	31
33	The juvenile systemic sclerosis clinic: an interdisciplinary approach. *Pediatric Rheumatology*, **2012**, 10,	3.5	78
32	A preliminary disease severity score for juvenile systemic sclerosis. *Arthritis and Rheumatism*, **2012**, 64, 4143-50		33
31	Tocilizumab in JIA patients who have inadequate response to anti-tumour necrosis factor therapy. *Pediatric Rheumatology*, **2011**, 9,	3.5	78
30	Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. *Clinical and Experimental Rheumatology*, **2011**, 29, 117-24	2.2	31
29	EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part I: Overall methodology and clinical characterisation. *Annals of the Rheumatic Diseases*, **2010**, 69, 790-7	2.4	140
28	Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. *Arthritis Care and Research*, **2010**, 62, 63-72	4.7	164
27	The Paediatric Rheumatology International Trials Organisation provisional criteria for the evaluation of response to therapy in juvenile dermatomyositis. *Arthritis Care and Research*, **2010**, 62, 1533-41	4.7	63
26	Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents. *Journal of Rheumatology*, **2009**, 36, 1078-82	4.1	58
25	Factors affecting survival in juvenile systemic sclerosis. *Rheumatology*, **2009**, 48, 119-22	3.9	61
24	Use of adalimumab in patients with juvenile idiopathic arthritis refractory to etanercept and/or infliximab. *Clinical Rheumatology*, **2009**, 28, 985-8	3.9	26
23	Basal ganglia and internal capsule stroke in childhood--risk factors, neuroimaging, and outcome in a series of 28 patients: a tertiary hospital experience. *Journal of Child Neurology*, **2009**, 24, 685-91	2.5	19
22	The prospective juvenile systemic sclerosis inceptions cohort http://www.juvenile-scleroderma.com. *Pediatric Rheumatology*, **2008**, 6,	3.5	78

21	Neuromyelitis optica associated with systemic autoimmune diseases in children. *Pediatric Rheumatology*, **2008**, 6,	3.5	78
20	13.4 High frequency of CNS involvement in linear scleroderma of the face. *Pediatric Rheumatology*, **2008**, 6, S27	3.5	78
19	14.2 Causes of early death in juvenile onset systemic lupus erythematosus (JSLE). *Pediatric Rheumatology*, **2008**, 6,	3.5	78
18	Hepatitis A-associated macrophage activation syndrome in children with systemic juvenile idiopathic arthritis: report of 2 cases. *Journal of Rheumatology*, **2008**, 35, 166-8	4.1	14
17	Global damage in systemic juvenile idiopathic arthritis: preliminary early predictors. *Journal of Rheumatology*, **2008**, 35, 1151-6	4.1	13
16	The Pediatric Rheumatology European Society/American College of Rheumatology/European League against Rheumatism provisional classification criteria for juvenile systemic sclerosis. *Arthritis and Rheumatism*, **2007**, 57, 203-12		127
15	Clinical characteristics of children with Juvenile Systemic Sclerosis: follow-up of 23 patients in a single tertiary center. *Pediatric Rheumatology*, **2007**, 5, 6	3.5	30
14	Chronic infantile neurological cutaneous and articular syndrome: two new cases with rare manifestations. *Acta Paediatrica, International Journal of Paediatrics*, **2007**, 90, 1076-1079	3.1	14
13	Ocular involvement in children with localised scleroderma: a multi-centre study. *British Journal of Ophthalmology*, **2007**, 91, 1311-4	5.5	86
12	Systemic sclerosis in childhood: clinical and immunologic features of 153 patients in an international database. *Arthritis and Rheumatism*, **2006**, 54, 3971-8		156
11	Hypertrophic osteoarthropathy in two children with cholestatic hepatic disease. *Acta Paediatrica, International Journal of Paediatrics*, **2005**, 94, 1152-5	3.1	1
10	Localized scleroderma in childhood is not just a skin disease. *Arthritis and Rheumatism*, **2005**, 52, 2873-81		258
9	Hypertrophic osteoarthropathy in two children with cholestatic hepatic disease. *Acta Paediatrica, International Journal of Paediatrics*, **2005**, 94, 1152-1155	3.1	2
8	Use of infliximab in patients with systemic juvenile idiopathic arthritis refractory to etanercept. *Clinical and Experimental Rheumatology*, **2005**, 23, 545-8	2.2	15
7	De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. *Arthritis and Rheumatism*, **2002**, 46, 3340-8		617
6	Etanercept in systemic juvenile idiopathic arthritis. *Clinical and Experimental Rheumatology*, **2002**, 20, 723-6	2.2	29
5	Cholestasis in juvenile dermatomyositis: report of three cases. *Arthritis and Rheumatism*, **2001**, 44, 1139-42		12
4	Chronic infantile neurological cutaneous and articular/neonatal onset multisystem inflammatory disease syndrome: ocular manifestations in a recently recognized chronic inflammatory disease of childhood. *JAMA Ophthalmology*, **2000**, 118, 1386-92		103

3	Interferon-beta1a-induced juvenile chronic arthritis in a genetically predisposed young patient with multiple sclerosis: comment on the case report by Levesque et al. *Arthritis and Rheumatism*, **2000**, 43, 1190		7
2	Favourable outcome in 135 children with juvenile systemic sclerosis: results of a multi-national survey. *Rheumatology*, **2000**, 39, 556-9	3.9	89
1	Cross-cultural adaptation and validation of an Argentine Spanish Version of the Stanford Childhood Health Assessment Questionnaire. *Arthritis and Rheumatism*, **1998**, 11, 382-90		11